Remi Bader says her binge eating worsened after she stopped taking Ozempic

In January 2023, the plus-size fashion creator Remi Bader said her binge eating became significantly worse after she stopped taking Ozempic. Bader told People she had been prescribed the drug while she was prediabetic ^[1]. Hers was one of the first widely read accounts to connect GLP-1 medications to disordered eating.

Ozempic is approved to treat Type 2 diabetes, and its active ingredient, semaglutide, is also approved to treat obesity under the name Wegovy. Mounjaro is approved for diabetes and Zepbound for obesity; both are tirzepatide, and both are made by Eli Lilly. Novo Nordisk, the maker of Ozempic, has said it does not support off-label use of its medications ^[1].

Other public figures have described how these drugs change appetite. Savannah Chrisley said she stopped her first weight-loss drug because she disliked how it affected her appetite, and later lost 25 pounds on tirzepatide ^[1]. Chrissy Teigen, who said she turned to Ozempic after a 2020 miscarriage, described the drop in hunger cues as "frustrating," adding, "It was frustrating for me because I know that logically you need food to have energy" ^[1]. Bunnie XO said in December 2025 that she had "a bout of suicidal ideation" while taking a GLP-1 ^[1].

Others have reported very different experiences. Renee Graziano said she had lost 52 pounds by May 2025 while taking Mounjaro ^[1]. Serena Williams said she used a GLP-1 after the birth of her second child and that her blood sugar levels improved and her joints felt lighter ^[1]. Meghan Trainor said she used Mounjaro after her second pregnancy alongside work with a dietitian and a trainer ^[1]. Kelly Clarkson said the drug she takes is not Ozempic ^[1].

What is not known: how often binge eating worsens when a GLP-1 is stopped, whether that happens in people with no history of disordered eating, and what the biological reason would be. Individual accounts like Bader's do not establish cause and effect. Her dose, how long she took Ozempic and when she stopped have not been disclosed.

Why it matters for patients

Appetite is the effect most people notice on these drugs, and several of the accounts above describe it directly — a reduced interest in food while taking the medication, or hunger returning in a different way once it is stopped ^[1]. For someone with a history of binge eating, that shift can matter as much as the number on the scale.

People deciding about a GLP-1 have to weigh not only what happens during treatment but what happens after it ends. Bader's account is one person's public report, not a study result, and it does not show that Ozempic caused the change she described. It also does not show how common that experience is.

The distinction between approved and off-label use is part of this picture. Ozempic is approved for Type 2 diabetes, Wegovy for obesity, and Mounjaro for diabetes and Zepbound for obesity, so a prescription written for weight loss with a diabetes drug is off-label, and Novo Nordisk has said it does not support that use ^[1].

Mental health effects have also been raised by people taking these drugs. Bunnie XO's description of suicidal ideation while on a GLP-1 is one such report ^[1]. Whether GLP-1 medications contribute to such symptoms, and how often, has not been established by the accounts described here.

What happens next

No follow-up study or formal review tied to Bader's account has been reported. Whether regulators, drugmakers or researchers will publish data on eating behavior after stopping a GLP-1 remains undisclosed.